Gastrointestinal GI Stent Market: as Boston Scientific's own December 2025 recall letter for its market-leading AXIOS platform demonstrates, even the most clinically established EUS-guided drainage stent can face a deployment-mechanism failure serious enough to trigger an FDA early alert, so the market's real competitive lesson is that manufacturing consistency and post-market surveillance rigor matter as much as device design innovation, and hospitals evaluating GI stent suppliers now need to weight quality system track record alongside clinical indication breadth.

The global gastrointestinal GI stent market size was USD 524.6 Million in 2025 and is expected to register a revenue CAGR of 5.4% during the forecast period. Market revenue growth is driven by factors such as the documented global GI cancer burden requiring palliative stenting, Olympus' integration of Taewoong Medical's GI metallic stent portfolio into a combined endoscope-and-stent platform, and EUS-guided stent applications expanding beyond traditional biliary and colonic indications. The first driving factor is the documented scale of global GI cancer burden, which GLOBOCAN 2022 data places at 1.9 million colorectal, 970,000 gastric, and 511,000 pancreatic cases annually, a substantial share of which require palliative stenting at some point in the disease course. Biliary stents account for approximately 42% of total 2025 market revenue, reflecting biliary obstruction's position as the most common GI stenting indication. The second driving factor is Olympus' integration of Taewoong Medical's Niti-S metallic stent portfolio into a combined endoscope-and-stent commercial platform following its January 2024 acquisition. The third driving factor is EUS-guided stent applications expanding beyond traditional biliary and colonic indications into new drainage procedures for gallbladder and pancreatic pseudocyst management. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a single stent platform accumulates additional cleared clinical indications over its commercial lifetime, which converts one core stent design into a widening set of billable procedure applications without requiring an entirely new device development programme. Once a stent platform earns its baseline biliary or colonic indication, each additional cleared application, such as EUS-guided gallbladder or pancreatic pseudocyst drainage, extends the platform's addressable procedure volume without a new device design, so platform value compounds as its labeled indication set widens around the same core stent architecture. As a result, demand and revenue share are concentrating around platforms with the broadest labeled indication set and the most extensive combined endoscope-and-accessory commercial relationship, and the forecast tilts toward integrated manufacturers over single-product stent specialists. For example, TaeWoong Medical, now an Olympus subsidiary following the January 2024 acquisition, received FDA 510(k) clearance for its Niti-S Spaxus EUS-guided drainage stent, extending the combined Olympus-Taewoong portfolio's labeled indication set into pancreatic pseudocyst and walled-off necrosis drainage. These are some of the key factors driving revenue growth of the market.

Because even long-established, market-leading stent platforms can experience manufacturing or design issues serious enough to trigger a recall, hospitals and physicians face real uncertainty about device reliability that can affect purchasing decisions and clinical confidence independent of a platform's overall track record.

In December 2025, Boston Scientific notified customers of a deployment issue affecting certain AXIOS Stent and Electrocautery Enhanced Delivery System units, in which the stent could fail to expand properly during deployment, a problem the FDA characterised as a potentially high-risk device issue in an early alert, with the company reporting 167 serious injuries and three deaths as of late December 2025, though the company noted the deaths were associated with off-label or investigational use outside the device's approved indications.

Specialist technique requirements for EUS-guided stent placement are a second constraint, since these procedures require training beyond standard ERCP or colonoscopy competency, which limits adoption to centres with adequately trained interventional endosonographers.

Reimbursement variability for advanced stent indications is a third constraint, since coverage for newer EUS-guided applications varies meaningfully by country and payer, which creates inconsistent adoption even where clinical guidelines support expanded stent use.

These factors substantially limit gastrointestinal GI stent market growth over the forecast period.

The clearest driver of demand is the documented scale of global GI cancer burden, which frequently requires palliative stenting to relieve obstruction when curative surgical resection is not feasible. A malignant GI obstruction that cannot be surgically resected still requires a way to restore luminal patency for the patient's remaining quality of life, so stent placement becomes a core palliative care intervention independent of advances in cancer treatment itself. GLOBOCAN 2022 data documents 1.9 million colorectal, 970,000 gastric, and 511,000 pancreatic cancer cases annually worldwide, and the American Cancer Society separately reported approximately 152,810 new US colorectal cancer cases in 2024. The effect on the market is that baseline GI stent demand tracks global cancer incidence trends closely, providing a stable demand floor beneath the market's platform-specific competitive dynamics. These are some of the key factors driving revenue growth of the market.

The second driver is Olympus' integration of Taewoong Medical's GI metallic stent portfolio into a combined endoscope-and-stent commercial platform following the January 2024 acquisition closing. A hospital or endoscopy centre that already purchases its endoscopes and visualization systems from a single manufacturer has a natural incentive to source compatible stent products from the same relationship where clinically appropriate, so combining an established endoscope franchise with a stent portfolio under one commercial roof extends that relationship's addressable spend. TaeWoong Medical, now an Olympus subsidiary, received FDA 510(k) clearance for its Niti-S Spaxus EUS-guided drainage stent, a fully covered, self-expanding metallic device with a bi-flange design for lumen apposition, extending the combined portfolio's labeled indication set into pancreatic pseudocyst and walled-off necrosis drainage. The effect on the market is that Olympus is positioned to compete for GI stent purchasing decisions as an extension of its existing endoscope commercial relationships, not solely on stent product merits alone. These are some of the key factors driving revenue growth of the market.

Boston Scientific's own December 2025 recall notice for its market-leading AXIOS platform is a reminder that even the most established GI stent franchise can face a serious deployment-mechanism issue. Manufacturing consistency, not just clinical indication breadth, now belongs in every procurement evaluation.

The third driver is the expansion of EUS-guided stent applications beyond traditional biliary and colonic indications into new drainage procedures for gallbladder and pancreatic pseudocyst management. EUS-guided drainage offers a less invasive alternative to surgical drainage for patients who are poor surgical candidates, so as EUS-guided stent platforms accumulate additional cleared indications for gallbladder and pancreatic drainage, the category addresses a growing set of patients who previously had limited non-surgical options. The effect on the market is that EUS-guided stent applications represent the category's fastest-expanding clinical use case, even as they also carry the newest and least mature safety and manufacturing track record relative to established biliary and esophageal stent designs. These are some of the key factors driving revenue growth of the market.

However, the gastrointestinal GI stent market faces severe adoption constraints from device-related safety events affecting even established platforms and the specialist technique requirements for EUS-guided stent placement.

Because even long-established, market-leading stent platforms can experience manufacturing or design issues serious enough to trigger a recall, hospitals and physicians face real uncertainty about device reliability that can affect purchasing decisions and clinical confidence independent of a platform's overall track record.

In December 2025, Boston Scientific notified customers of a deployment issue affecting certain AXIOS Stent and Electrocautery Enhanced Delivery System units, in which the stent could fail to expand properly during deployment, a problem the FDA characterised as a potentially high-risk device issue in an early alert, with the company reporting 167 serious injuries and three deaths as of late December 2025, though the company noted the deaths were associated with off-label or investigational use outside the device's approved indications.

Specialist technique requirements for EUS-guided stent placement compound this, since these procedures require training beyond standard ERCP or colonoscopy competency, which limits adoption to centres with adequately trained interventional endosonographers even where a stent platform's indication and safety profile support broader use.

Reimbursement variability for advanced stent indications is the third constraint, since coverage for newer EUS-guided applications varies meaningfully by country and payer, which creates inconsistent adoption even where clinical guidelines support expanded stent use.

These factors substantially limit gastrointestinal GI stent market growth over the forecast period.

Based on product, the global gastrointestinal GI stent market is segmented into biliary stents, esophageal stents, colonic stents, duodenal and pancreatic stents, and EUS-guided drainage stents. Biliary stents hold the largest revenue share, because biliary obstruction from malignant and benign causes represents the single most common GI stenting indication, which suits a market where the highest-volume clinical indication commands the largest revenue category. Esophageal stents remain established for malignant dysphagia palliation and benign stricture management, but their overall volume trails biliary indications. EUS-guided drainage stents are expected to register the fastest revenue growth rate in the global gastrointestinal GI stent market over the forecast period, driven by expanding clinical indications for gallbladder and pancreatic pseudocyst drainage, which is why manufacturers continue to pursue new labeled indications for this newer stent category.

Based on material, the global gastrointestinal GI stent market is segmented into plastic stents, self-expanding metal stents, and covered SEMS. Self-expanding metal stents hold the largest revenue share, because they provide longer patency than plastic alternatives for malignant obstruction, which ties directly back to the GI cancer palliation demand described in the market's primary demand driver. Covered SEMS are expected to register the fastest revenue growth rate in the global gastrointestinal GI stent market over the forecast period, driven by their combination of metal stent patency with reduced tumor ingrowth risk, which is why manufacturers increasingly prioritise covered designs across their newest product launches.

GI cancer palliation application is expected to account for the largest revenue share in the global gastrointestinal GI stent market during the forecast period

Based on application, the global gastrointestinal GI stent market is segmented into biliary disease, GI cancer palliation, and benign GI stricture management. Biliary disease holds the largest revenue share, reflecting the volume of biliary obstruction cases across both malignant and benign causes. GI cancer palliation is expected to register the fastest revenue growth rate in the global gastrointestinal GI stent market over the forecast period, driven by the documented global GI cancer burden and expanding EUS-guided drainage applications for pancreatic and gallbladder indications.

Based on regional analysis, the gastrointestinal GI stent market in North America accounted for largest revenue share in 2025. The United States leads because the concentration of GI cancer treatment centres and interventional endoscopy programmes sustains the highest stenting procedure volume globally, and because Boston Scientific, Olympus, and Cook Medical all maintain their primary commercial presence in the US market. The December 2025 AXIOS recall specifically affects the US market most directly given the device's concentration of use in American interventional GI programmes. The scale of US GI cancer incidence anchors a domestic stent market large enough to sustain multiple competing platforms simultaneously.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, France, and the United Kingdom represent the three largest national markets within Europe. The European Society of Gastrointestinal Endoscopy has endorsed self-expanding metal stents for malignant colonic and biliary obstruction, including colonic stenting as a bridge-to-surgery strategy, reinforcing clinical guideline support for stent use across the region. The result is steady rather than rapid growth, shaped more by national health system reimbursement negotiation than by underlying patient demand.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. South Korea and Japan represent two of the most established national markets within the region, reflecting Taewoong Medical's Korean manufacturing base and Olympus' Japanese corporate headquarters. China's rapidly expanding GI cancer treatment infrastructure leaves considerably more room for growth than in the already stent-saturated North American market.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national markets within the region, with private hospital networks driving early adoption of advanced stent platforms among higher-income patients. The ongoing Iran-US sanctions and the resulting Strait of Hormuz shipping disruption have raised freight and import costs for the nitinol alloy and precision delivery system components that Latin American device distributors depend on, an effect expected to run through 2026 and slow GI stent adoption beyond Brazil's and Mexico's main urban centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial markets within the region. Saudi Arabia's expanding oncology treatment infrastructure and the UAE's regional distribution hubs represent the primary investment centres for GI stent adoption. Saudi Arabia is the most established market on the continent, while the Gulf states outside it are still building the interventional endoscopy infrastructure needed to support advanced stent platforms at scale.